Skip to NavigationSkip to content

Pharmafile - Research and Development News

- Novartis' new MS drug to cost $88,000 a year - Measles outbreak spurs New York County to ban all unvaccinated children from public spaces -...
Johnson and Johnson has unveiled new Phase 3 data on its antihistamine-releasing contact lens, showing that the investigational product led to...
Lord Jim O’Neill, an economist and former government advisor on antimicrobial resistance (AMR), has accused the pharmaceutical industry of “spewing...
Rockland County, New York State, is taking serious measures to combat its biggest measles outbreak in decades, making the decision to ban all...
AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry...
Children who were treated with methylphenidate-based medications (i.e. Ritalin) for conditions such as ADHD were at significantly greater risk of...
Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will cost $88,000 a...
OxyContin drugmaker Purdue Pharma has agreed to pay nearly $270 million to the state of Oklahoma, in order to settle a case brought about by the...
Novo Nordisk has revealed new dose-specific Phase 3a data for its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide, indicating that the...
Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new data which...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches